Reoperation Risk for Nonpalpable Breast Lesions Higher for DCIS

Share this content:
Reoperation Risk for Nonpalpable Breast Lesions Higher for DCIS
Reoperation Risk for Nonpalpable Breast Lesions Higher for DCIS

THURSDAY, Dec. 29, 2016 (HealthDay News) -- For women undergoing wire-guided breast conserving surgery (BCS) for nonpalpable breast lesions, the risk of reoperation is higher for those with ductal carcinoma in situ (DCIS) than those with invasive breast cancer (IBC), according to a study published online Dec. 21 in JAMA Surgery.

Linnea Langhans, M.D., from the University of Copenhagen in Denmark, and colleagues examined the reoperation rate after wire-guided BCS in a nationwide study involving women with histologically verified nonpalpable IBC or DCIS. Wire-guided BCS was performed in 4,118 women.

The researchers found that 17.6 percent of the women underwent reoperation: 14.4 percent were reexicisions and 3.2 percent were mastectomies. Reoperation was performed for significantly more patients with DCIS than IBC (37.3 versus 13.4 percent; adjusted odds ratio, 3.82; P < 0.001). Positive margins were still present in 16.4 percent of patients after reoperation. Patients with DCIS had significantly higher risk of repeated positive margins compared with those with IBC (unadjusted odds ratio, 2.21; P < 0.001). Patients with lobular versus ductal carcinoma had significantly increased risk of reoperation (adjusted odds ratio, 1.44; P = 0.02). A subsequent completion mastectomy was performed in 4.9 percent of patients, with no difference in the type of reoperation for those with DCIS and IBC.

"A lower reoperation rate after wire-guided BCS was found in this study than those shown in previous studies," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Post-Deployment Screening Has Limited Benefit in U.K. Military

Post-Deployment Screening Has Limited Benefit in U.K. Military

Screening based on tailored advice does not reduce prevalence of disorders or increase help-seeking

Excess BMI Ups Risk of T1DM in Autoantibody-Positive Relatives

Excess BMI Ups Risk of T1DM in Autoantibody-Positive ...

Increased diabetes progression risk occurred at lower cumulative excess BMI index in children <12

Baricitinib Associated With Significant Improvement in RA

Baricitinib Associated With Significant Improvement in RA

Findings versus placebo, adalimumab in patients non-responsive to methotrexate

is free, fast, and customized just for you!

Already a member?

Sign In Now »